收到日
20150204
161806/2

Claims:

1. A use of a pharmaceutical combination for preparing drugs for treating and/or preventing a cancer, wherein the pharmaceutical combination comprising an active ingredient (a) of a taxane compound; and an active ingredient (b) of plinabulin, and the cancer has a tumor size of > 3cm.

2. The use of Claim 1, wherein the taxane compound comprises paclitaxel, docetaxel, and abraxane.

3. The use of Claim 1, wherein the combination consists of docetaxel and plinabulin.

4. The use of Claim 1, wherein the cancer has a tumor size of >5cm.

5. The use of Claim 1, wherein the cancer has a tumor size of >7cm.

6. The use of Claim 1, wherein the cancer selected from the group consisting of lung cancer, colon cancer, liver cancer, breast cancer, prostate cancer, and multiple myeloma.

7. A kit, containing:

(i) a first container containing a first medicament which comprises a taxane compound as an active ingredient (a) and an optional pharmaceutically acceptable carrier; and

(ii) a second container containing a second medicament which comprises plinabulin as an active ingredient (b) and an optional pharmaceutically acceptable carrier;

(iii) an instruction recording an administration of the active ingredient (a) in combination with the active ingredient (b) for treating and/or preventing cancer;

wherein there are 8 first medicaments at 20 mg per vial and 2 second medicaments at 80 mg per vial in a single kit.

8. A pharmaceutical composition for treating a cancer with a tumor size of > 3cm, wherein it comprises:

an active ingredient (a) of taxane;

an active ingredient (b) of plinabulin; and

(c) a pharmaceutical acceptable carrier;

wherein the ratio (mg: mg) of active ingredient (a) to active ingredient (b) is 1: 100 to 50: 1; preferably, 1.5:1 to 4:1, and/or

the total amount of the active ingredient (a) and the active ingredient (b) is 1-99wt%; and more preferably, 5-90wt% of the composition.

9. A use of plinabulin for preparation of a medicine used to reduce side effect of taxane, wherein the side effect is selected from the group consisting of neutropenia, anemia, febrile neutropenia, thrombocytopenia and the combination thereof.

10. The use of Claim 9, wherein the neutropenia is a grade 3 neutropenia or a grade 4 neutropenia.

11. A method for reducing side effect of taxane, wherein it comprises a step of administrating plinabulin to the subject in need prior to, at same time or after administrating a taxane compound, and the side effect is selected from the group consisting of neutropenia, anemia, febrile neutropenia ,

thrombocytopenia and the combination thereof.

12. The method of Claim 11, wherein the plinabulin is injected 1-24 hours after administration of docetaxel.

13. The method of Claim 11, wherein the side effect is selected from the group consisting of neutropenia and anemia.

14. The method of Claim 13, wherein the neutropenia is a grade 3 neutropenia or a grade 4 neutropenia.

15. The method of Claim 11, wherein the subject is a NSCLC patient.

CLAIMS

1. Use of plinabulin in the preparation of a medicament for the treatment of a taxane-induced neutropenia in a subject having a taxane-induced neutropenia.

2. The use of claim 1, wherein the medicament is for administration prior to administration of the taxane.

3. The use of claim 1, wherein the medicament is for administration after administration of the taxane.

4. The use of any one of claims 1 to 3, wherein the medicament is for inducing a neutropenia rate that is lower than that induced by taxane alone.

5. The use of any one of claims 1 to 4, wherein the taxane is docetaxel.

6. The use of claim 5, wherein the taxane-induced neutropenia is induced by administration of docetaxel at a dose of about 45 mg/m^2 to 120 mg/m^2.

7. The use of claim 6, wherein the taxane-induced neutropenia is induced by administration of docetaxel at a dose of about 50 mg/m^2 to 75 mg/m^2.

8. The use of any one of claims 1 to 4, wherein the taxane is paclitaxel.

9. The use of claim 8, wherein the taxane-induced neutropenia is induced by administration of paclitaxel at a dose of about 50 to 250 mg/m^2.

10. The use of any one of claims 1 to 4, wherein the taxane is abraxane.

11. The use of any one of claims 1 to 10, wherein the medicament comprises a dose of plinabulin of about 10 to 50 mg/m^2.

12. The use of claim 11, wherein the medicament comprises a dose of plinabulin of about 20 mg/m^2 or 30 mg/m^2.

13. The use of any one of claims 1 to 12, wherein the weight ratio of taxane dosage and plinabulin dosage is about 1.5:1 to 4:1.

14. The use of claim 1 or 3, wherein the medicament is for administration about 1 to 24 hours after taxane administration.

15. The use of claim 14, wherein the medicament is for administration about 2 hours after taxane administration.

16. The use of any one of claims 1 to 15, wherein the medicament is for reducing a neutropenia rate by at least 4% for grade 3 neutropenia.

17. The use of any one of claims 1 to 16, wherein the medicament is for reducing a neutropenia rate by at least 15% for grade 4 neutropenia

18. Use of plinabulin in the preparation of a medicament for use in combination with abraxane for the treatment of cancer in a subject having cancer.

19. The use of claim 18, wherein the medicament is for administration at least 1 hour after abraxane administration.

20. The use of claim 18 or 19, wherein the weight ratio of abraxane dosage and plinabulin dosage is about 1.5:1 to 4:1.

21. The use of any one of claims 18 to 20, wherein the cancer is selected from lung cancer, colon cancer, gastric cancer, liver cancer, breast cancer, prostate cancer, or multiple myeloma.

22. Use of plinabulin in the preparation of a medicament for use in combination with a taxane for the treatment of cancer in a subject having a tumor size of greater than 3 cm.

23. The use of claim 22, wherein the medicament is for administration at least 1 hour after taxane administration.

24. The use of claim 22 or 23, wherein the subject has a tumor size of greater than 5 cm.

25. The use of any one of claims 22 to 24, wherein the subject has a tumor size of greater than 7 cm.